Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94
AuthorsMichalowska, M. M.
Anton-Rodriguez, Jose M
Karikari, T. K.
Ashton, N. J.
Carter, S. F.
AffiliationWolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractAmyloid-beta (Aβ) deposition is common in cognitively unimpaired (CU) elderly >85 years. This study investigated amyloid distribution and evaluated three published in vivo amyloid-PET staging schemes from a cognitively unimpaired (CU) cohort aged 84.9 ± 4.3 years (n = 75). SUV-based principal component analysis (PCA) was applied to 18F-flutemetamol PET data to determine an unbiased regional covariance pattern of tracer uptake across grey matter regions. PET staging schemes were applied to the data and compared to the PCA output. Concentration of p-tau181 was measured in blood plasma. The PCA revealed three distinct components accounting for 91.2% of total SUV variance. PC1 driven by the large common variance of uptake in neocortical and striatal regions was significantly positively correlated with global SUVRs, APOE4 status and p-tau181 concentration. PC2 represented mainly non-specific uptake in typical amyloid-PET reference regions, and PC3 the occipital lobe. Application of the staging schemes demonstrated that the majority of the CU cohort (up to 93%) were classified as having pathological amount and distribution of Aβ. Good correspondence existed between binary (+/-) classification and later amyloid stages, however, substantial differences existed between schemes for low stages with 8-17% of individuals being unstageable, i.e., not following the sequential progression of Aβ deposition. In spite of the difference in staging outcomes there was broad spatial overlap between earlier stages and PC1, most prominently in default mode network regions. This study critically evaluated the utility of in vivo amyloid staging from a single PET scan in CU elderly and found that early amyloid stages could not be consistently classified. The majority of the cohort had pathological Aβ, thus, it remains an open topic what constitutes abnormal brain Aβ in the oldest-old and what is the best method to determine that.
CitationMichalowska MM, Herholz K, Hinz R, Amadi C, McInnes L, Anton-Rodriguez JM, et al. Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94. Molecular psychiatry. 2022 Jul 20. PubMed PMID: 35858992. Epub 2022/07/21. eng.
- Estimation of amyloid distribution by [<sup>18</sup>F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.
- Authors: Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, Ismail A, Farrar G, Buckley C, Smith APL
- Issue date: 2018 Oct
- Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
- Authors: Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, Borroni E, Janelidze S, Ohlsson T, Jögi J, Ossenkoppele R, Palmqvist S, Mattsson-Carlgren N, Klein G, Stomrud E, Hansson O
- Issue date: 2022 Feb 1
- Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
- Authors: Blazhenets G, Frings L, Sörensen A, Meyer PT, Alzheimer’s Disease Neuroimaging Initiative.
- Issue date: 2021 Jun 1
- Multitracer model for staging cortical amyloid deposition using PET imaging.
- Authors: Collij LE, Heeman F, Salvadó G, Ingala S, Altomare D, de Wilde A, Konijnenberg E, van Buchem M, Yaqub M, Markiewicz P, Golla SSV, Wottschel V, Wink AM, Visser PJ, Teunissen CE, Lammertsma AA, Scheltens P, van der Flier WM, Boellaard R, van Berckel BNM, Molinuevo JL, Gispert JD, Schmidt ME, Barkhof F, Lopes Alves I, ALFA Study, for the Alzheimer's Disease Neuroimaging Initiative., AMYPAD Consortium.
- Issue date: 2020 Sep 15
- Longitudinal tau PET in ageing and Alzheimer's disease.
- Authors: Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, Weigand SD, Therneau TM, Knopman DS, Gunter JL, Jones DT, Graff-Radford J, Kantarci K, Roberts RO, Mielke MM, Machulda MM, Petersen RC
- Issue date: 2018 May 1